8-(2-(4-Hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate → Lovastatin

HRID 582457

Reaktionsgleichung

Reaktionsgleichung von HRID 582457
[CH3:1][CH2:2][C@@H:3]([C:5]([O:7][C@@H:8]1[C@@H:13]2[C@@H:14]([CH2:19][CH2:20][C@H:21]3[O:27][C:25](=[O:26])[CH2:24][C@H:23]([OH:28])[CH2:22]3)[C@@H:15]([CH3:18])[CH:16]=[CH:17][C:12]2=[CH:11][C@H:10]([CH3:29])[CH2:9]1)=[O:6])[CH3:4].[CH3:30][CH:31]1[CH:40]=[C:39]2[CH:34]([CH:35]([CH2:42][CH2:43][CH:44]3[CH2:49][CH:48]([OH:50])[CH2:47][C:46](=[O:51])[O:45]3)[CH:36]([CH3:41])[CH:37]=[CH:38]2)[CH:33]([O:52][C:53](=[O:58])[CH:54]([CH3:57])[CH2:55][CH3:56])[CH2:32]1>>[CH3:1][CH2:2][C@@H:3]([C:5]([O:7][C@@H:8]1[C@@H:13]2[C@@H:14]([CH2:19][CH2:20][C@H:21]3[O:27][C:25](=[O:26])[CH2:24][C@H:23]([OH:28])[CH2:22]3)[C@@H:15]([CH3:18])[CH:16]=[CH:17][C:12]2=[CH:11][C@H:10]([CH3:29])[CH2:9]1)=[O:6])[CH3:4].[CH3:56][CH2:55][C@@H:54]([C:53]([O:52][C@@H:33]1[C@@H:34]2[C@@H:35]([CH2:42][CH2:43][C@@H:44]([OH:6])[CH2:49][C@@H:48]([OH:50])[CH2:47][C:46]([OH:45])=[O:51])[C@@H:36]([CH3:41])[CH:37]=[CH:38][C:39]2=[CH:40][C@H:31]([CH3:30])[CH2:32]1)=[O:58])[CH3:57]

Komponenten

4

Edukt 2

HCID 39628-(2-(4-Hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoateHCID 53232Lovastatin

Produkt 2

HCID 53232LovastatinHCID 64727Lovastatin Acid

Versuchsvorschrift

Lovastatin is chemically represented as [1S-[1α(R*),3α,7β,8β(2S*,4S*),8αβ]]-2-methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, and strains producing the compound also produce an acid form of lovastatin, i.e., mevinolinic acid, which is converted into lovastatin(mevinolin) as a lactone form in the course of isolation and recovery.

Aufarbeitung

  1. customproducing the compound

Quellen und Nachweise

ORD-Eintrag
ord-9bbb0eec042f4c9192f3c1a2906d5c11
Quelldatensatz
uspto-grants-1999_07
Patentnummer
US05925551

Verknüpfte Notizen

Wird geladen…